Skip to content

A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines

A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180321001
Enrollment
69
Registered
2018-03-21
Start date
2017-09-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) Age between 18&#45

Interventions

Control group : Chorpheniramine 10 mg/amp
1 ampule and cetirizine 10 mg 7 tabs,Chorpheniramine 10 mg/amp
1 ampule&#44
Dexamethasone 5 mg/amp
cetirizine 10 mg 7 tabs&#44
and prednisolone 5 mg 20 tabs
Active Comparator Drug,Active Comparator Drug,Active Comparator Drug
CPM IV + Zyrtec po,CPM IV + Dexa IV + Zyrtec po,CPM IV + Dexa IV + Zyrtec po + prednisolone po

Sponsors

Rachada
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as 1. eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema 2. pruritus or occasional burning sensation 3. skin returning to normal appearance, usually within 1-24 hours

Exclusion criteria

Exclusion criteria: 1. patients who have urticarial for more than 48 hours 2. have severe underlying disease such as heart disease, kidney disease, liver disease 3. pregnancy 4. history of CPM, steroid, antihistamines allergy 5. history of antihistamine or steroid uses within 48 hours before ED visit 6. diabetes mellitus 7. suspected of more severe disease or severe allergic reaction 8. patients who don’t have puritus 9. patients who have history of chronic urticaria

Design outcomes

Primary

MeasureTime frame
Itch score 60 minutes visual analog scale

Secondary

MeasureTime frame
Recurrent rash 1 week Binary outcome

Countries

Thailand

Contacts

Public ContactPakhawadee Palungwachira

Chulalongkorn hospital

zaphyr_s@yahoo.com+66897704758

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026